KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Adaptive Biotechnologies (ADPT) EPS (Basic): 2018-2025

Historic EPS (Basic) for Adaptive Biotechnologies (ADPT) over the last 8 years, with Sep 2025 value amounting to $0.06.

  • Adaptive Biotechnologies' EPS (Basic) rose 127.27% to $0.06 in Q3 2025 from the same period last year, while for Sep 2025 it was -$0.53, marking a year-over-year increase of 60.45%. This contributed to the annual value of -$1.08 for FY2024, which is 30.77% up from last year.
  • As of Q3 2025, Adaptive Biotechnologies' EPS (Basic) stood at $0.06, which was up 135.29% from -$0.17 recorded in Q2 2025.
  • Adaptive Biotechnologies' 5-year EPS (Basic) high stood at $0.06 for Q3 2025, and its period low was -$0.48 during Q4 2023.
  • Moreover, its 3-year median value for EPS (Basic) was -$0.31 (2024), whereas its average is -$0.27.
  • As far as peak fluctuations go, Adaptive Biotechnologies' EPS (Basic) crashed by 71.43% in 2023, and later spiked by 127.27% in 2025.
  • Over the past 5 years, Adaptive Biotechnologies' EPS (Basic) (Quarterly) stood at -$0.44 in 2021, then skyrocketed by 36.36% to -$0.28 in 2022, then plummeted by 71.43% to -$0.48 in 2023, then surged by 54.17% to -$0.22 in 2024, then surged by 127.27% to $0.06 in 2025.
  • Its EPS (Basic) stands at $0.06 for Q3 2025, versus -$0.17 for Q2 2025 and -$0.20 for Q1 2025.